Hastalıkların tanı ve tedavi stratejilerinde miRNA ve diğer non-protein-coding RNA’lar

Öz

Son yıllarda yapılan tüm genom/fonksiyonel analiz çalışmaları insan genomunun yaygın olarak binlerce düzenleyici non-protein-coding RNA’lar (protein kodlamayan RNA) transkribe ettiğini ortaya koymuştur. Bunlar içerisinde mikro RNA’lar, small interfering RNA’lar, P-element-induced Wimply Testis (PIWI) interacting RNAs’lar ve çeşitli uzun non-protein-coding RNA’lar vardır. Bunlar içerisinde özellikle miRNA’lar son 20 yıldır biyomedikal disiplinlerde tanı ve tedavi stratejisi geliştirilmesinde oldukça geniş bir ilgi odağı haline gelmiştir. MikroRNA’lar kısa non-protein-coding RNA moleküllerinin bir sınıfıdır. Yüksek kapasiteli genomik ve biyoinformatik tekniklerin geleneksel moleküler biyoloji teknikleri ve deney hayvanı çalışmaları ile bütünleşmesi ile mikroRNA araştırmaları, günümüzde elde edilen ön bulguların laboratuvardan kliniğe ve halk sağlığına aktarılmasında önemli bir yer tutmaktadır. mikroRNA’lar küçük olmalarına rağmen çeşitli hücresel süreçlerle ilişkili olan post-transkripsiyonel gen ekspresyonunun önemli düzenleyicileridir. Bu nedenle mikroRNA’larda meydana gelen alterasyonlar tanımlanan bir dizi hastalığın patolojisi ile ilişkilendirilmiştir. Günümüze kadar, insanda 5000’den fazla miRNA keşfedilmiş ve bunların çoğu kanser, viral hastalıklar, immünite ile ilişkili hastalıklar, nörodejeneratif hastalıklar gibi birçok yaygın insan hastalığı ile ilişkilendirilmiştir. miRNA’ların yeni nesil biyomarker ve terapötik olma yolunda önemli potansiyelleri vardır.  

Anahtar kelimeler: miRNA, non-protein-coding RNA, tanı, tedavi, biyomarkır

Kaynakça

1. Gan L, X Midie, Z Yi, Z Xia, G Weijian. Focusing on long noncoding RNA dysregulation in gastric cancer. Tumor Biol 2015;36:129–141.
2. Meseure D, Alsibai KD, Nicolas A, Bieche I and Morillon A. Long noncoding RNAs as new architects in cancer epigenetics, prognostic biomarkers, and potential therapeutic targets. BioMed Research International 2015:14
3. J.M. Perkel. Visiting ‘noncodarnia’. BioTechniques 2013;54(6):301–304.
4. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. “Non-coding RNAs: regulators of disease.” J Pathol 2010;220(2):126-139.
5. Peng Qi, Xiang Du. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Modern Pathology 2013;26:155–165.
6. Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 2010;28(11):570-579.
7. Hrdlickova B, de Almeida RC, Borek Z, Withoff S. “Genetic variation in the non-coding genome: Involvement of micro-RNAs and long non-coding RNAs in disease”. Biochim Biophys Acta 2014;1842(10):1910-1922.
8. Siomi MC, Sato K, Pezic D, Aravin AA. PIWI-interacting small RNAs: the vanguard of genome defence. Nat Rev Mol Cell Bio 2011;12:246-258.

9. Hauptman N, Glavac D. MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer. Radiol Oncol 2013;47(4):311-318.
10. Mattick JS ve Makunin IV. Small regulatory RNAs in mammals. Human Molecular Genetics 2005;14(1):121-132.
11. Saydam F, Değirmenci İ, Güneş HV. MikroRNA’lar ve kanser. Dicle Tıp Dergisi 2011;38(1):113-120.
12. Takamizawa, J, Konishi, H, Yanagisawa, K, Tomida, S, Osada, H, Endoh, H, Harano, T, Yatabe, Y, Nagino, M, Nimura, Y. et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64(11):3753-3756
13. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med, 2010;363(19):1877.
14. Kim J, Bartel D. Allelic imbalance sequencing reveals that single-nucleotide polymorphisms frequently alter microRNAdirected repression. Nat Biotechnol 2009;27(5):472-477.
15. Gloss BS, Dinger ME. The specificity of long noncoding RNA expression, BBA - gene regulatory mechanisms. Biochim Biophys Acta. 2016;1859(1):16-22
16. Hydbring P, Badalian-Very G. “Clinical applications of microRNAs”.Version 3. F1000Res. 2013;2:136.
17. Huang Z, Huang D, Ni SJA, Peng ZL, Sheng WQ, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127(1):118-126.
18. Oksuz Z, Serin MS, Kaplan E, Dogen A, Tezcan S, Aslan G, Emekdas G, Sezgin O, Altintas E, Tiftik EN. Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma. Mol Biol Rep. 2015;42(3):713-720.
19. Giray BG, Emekdas G, Tezcan S, Ulger M, Serin MS, Sezgin O, Altintas E, Tiftik EN. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. Mol Biol Rep. 2014;41(7):4513-4519.
20. Hu YB, Li CB, Song N, Zou1 Y, Chen SD, Ren RJ and Wang G. Diagnostic value of microRNA for alzheimer’s disease: a systematic review and meta-analysis. Frontiers in Aging Neuroscience 2016;8(13):1-9.
21. Wong, LL, Wang J, Liew OW, Richards AM and Chen YT. MicroRNA and Heart Failure. Int. J Mol Sci 2016;17(4):1-31.
22. Yuan SX, Yang F, Yang Y et al. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients’ poor recurrence-free survival after hepatectomy. Hepatology 2012;56(6):2231–2241.
23. Yang J, Lin J, Liu T et al. Analysis of lncRNA expression profiles in non-small cell lung cancers (NSCLC) and their clinical subtypes. Lung Cancer 2014;85(2):110–115.
24. Kraus TF, Haider M, Spanner J, Steinmaurer M, Dietinger V, Kretzschmar HA. Altered long noncoding RNA expression precedes the course of parkinson's disease-a preliminary report. Mol Neurobiol 2016:1-9 [Epub ahead of print]
25. Research and markets. RNA (miRNA, RNAi & siRNA) therapy in oncology drug pipeline update 2014, Erişim: http://www.researchandmarkets.com/reports/2191815/. (Erişim tarihi: 10.05.2016).
26. Roberts TC and Wood MJA. Therapeutic targeting of non-coding RNAs. Essays Biochem 2013;(54):127–145.
27. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nature Cell Biology 2009;11: 228–34.
28. van der Ree MH, van der Meer AJ, van Nuenen AC, de Bruijne J, Ottosen S, Janssen HL, Kootstra NA, Reesink HW. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma. Aliment Pharmacol Ther 2016;43(1):102-113.
29. Zhi D, Zhao Y, Cui S, Chen H, Zhang S. Conjugates of small targeting molecules to non-viral vectors for the mediation of siRNA. Acta Biomater 2016;36:21-41.
30. Man DK, Chow MY, Casettari L, Gonzalez-Juarrero M, Lam JK. Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis. Advanced Drug Delivery Reviews 2016 Apr 22 [Epub ahead of print]
31. T. Gutschner, M. H¨ammerle, and S. Diederichs, MALAT1—a paradigm for long noncoding RNA function in cancer. Journal of Molecular Medicine 2013;91(7):791–801.